Showing results (71-80 of 85) with videos related to
Sort By:
Pageof 9
Cell Reports|March 17, 2015
The N-Terminal Domain of SIRT1 Is a Positive Regulator of Endogenous SIRT1-Dependent Deacetylation and Transcriptional OutputsFiorella Ghisays, Cynthia S Brace, Shawn M Yackly, et al.Geroscience|April 13, 2022
Age-related disruption of the proteome and acetylome in mouse hearts is associated with loss of function and attenuated by elamipretide (SS-31) and nicotinamide mononucleotide (NMN) treatmentJeremy A Whitson, Richard Johnson, Lu Wang, et al.Science (New York, N.Y.)|April 23, 2021
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic womenMihoko Yoshino, Jun Yoshino, Brandon D Kayser, et al.Cell Reports|September 30, 2016
NAMPT-Mediated NAD(+) Biosynthesis Is Essential for Vision In MiceJonathan B Lin, Shunsuke Kubota, Norimitsu Ban, et al.Cell Metabolism|January 10, 2017
Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in MiceKathryn F Mills, Shohei Yoshida, Liana R Stein, et al.Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|February 9, 2022
SIRT1 mediates hypoxic postconditioning- and resveratrol-induced protection against functional connectivity deficits after subarachnoid hemorrhageJulian V Clarke, Lindsey M Brier, Rachel M Rahn, et al.Cell Metabolism|November 7, 2007
Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzymeJavier R Revollo, Antje Körner, Kathryn F Mills, et al.Geriatrics & Gerontology International|May 4, 2026
Effect of Nicotinamide Mononucleotide on Retinal Thickness of Older Patients With Diabetes Mellitus: A Placebo-Controlled, Double-Blind StudyAkihiko Shiraki, Chikako Hara, Hiroshi Akasaka, et al.Geriatrics & Gerontology International|November 28, 2022
Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind studyHiroshi Akasaka, Hironori Nakagami, Ken Sugimoto, et al.BMC Cancer|December 15, 2010
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferaseUffe H Olesen, Jakob G Petersen, Antje Garten, et al.Pageof 9